Versiti Clinical Trials Services Partners with 4D Path to Accelerate Personalized Cancer Treatment Development
Versiti Clinical Trials Services (VCTS) has formed a partnership with 4D Path to enhance the development of personalized cancer treatments using predictive biomarker technology. This collaboration will make the Q-Plasia OncoReader (QPOR™) platform accessible to pharmaceutical companies and clinical research organizations associated with VCTS, providing them with advanced tools to analyze cancer responses.
MILWAUKEE & NEWTON, Mass.–(BUSINESS WIRE)– #4DPath–Versiti Clinical Trials Services (VCTS) has launched a partnership with 4D Path to bring cutting-edge treatment predictive biomarker technology to researchers developing lifesaving, personalized cancer treatments. The collaboration makes 4D Path’s Q-Plasia OncoReader (QPOR™) platform available to pharmaceutical companies and clinical research organizations working with VCTS, giving them powerful new tools to understand how individual cancers respond t